Cargando…

Substrate inhibition by the blockage of product release and its control by tunnel engineering

Substrate inhibition is the most common deviation from Michaelis–Menten kinetics, occurring in approximately 25% of known enzymes. It is generally attributed to the formation of an unproductive enzyme–substrate complex after the simultaneous binding of two or more substrate molecules to the active s...

Descripción completa

Detalles Bibliográficos
Autores principales: Kokkonen, Piia, Beier, Andy, Mazurenko, Stanislav, Damborsky, Jiri, Bednar, David, Prokop, Zbynek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: RSC 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8341658/
https://www.ncbi.nlm.nih.gov/pubmed/34458806
http://dx.doi.org/10.1039/d0cb00171f
_version_ 1783733958736871424
author Kokkonen, Piia
Beier, Andy
Mazurenko, Stanislav
Damborsky, Jiri
Bednar, David
Prokop, Zbynek
author_facet Kokkonen, Piia
Beier, Andy
Mazurenko, Stanislav
Damborsky, Jiri
Bednar, David
Prokop, Zbynek
author_sort Kokkonen, Piia
collection PubMed
description Substrate inhibition is the most common deviation from Michaelis–Menten kinetics, occurring in approximately 25% of known enzymes. It is generally attributed to the formation of an unproductive enzyme–substrate complex after the simultaneous binding of two or more substrate molecules to the active site. Here, we show that a single point mutation (L177W) in the haloalkane dehalogenase LinB causes strong substrate inhibition. Surprisingly, a global kinetic analysis suggested that this inhibition is caused by binding of the substrate to the enzyme–product complex. Molecular dynamics simulations clarified the details of this unusual mechanism of substrate inhibition: Markov state models indicated that the substrate prevents the exit of the halide product by direct blockage and/or restricting conformational flexibility. The contributions of three residues forming the possible substrate inhibition site (W140A, F143L and I211L) to the observed inhibition were studied by mutagenesis. An unusual synergy giving rise to high catalytic efficiency and reduced substrate inhibition was observed between residues L177W and I211L, which are located in different access tunnels of the protein. These results show that substrate inhibition can be caused by substrate binding to the enzyme–product complex and can be controlled rationally by targeted amino acid substitutions in enzyme access tunnels.
format Online
Article
Text
id pubmed-8341658
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher RSC
record_format MEDLINE/PubMed
spelling pubmed-83416582021-08-26 Substrate inhibition by the blockage of product release and its control by tunnel engineering Kokkonen, Piia Beier, Andy Mazurenko, Stanislav Damborsky, Jiri Bednar, David Prokop, Zbynek RSC Chem Biol Chemistry Substrate inhibition is the most common deviation from Michaelis–Menten kinetics, occurring in approximately 25% of known enzymes. It is generally attributed to the formation of an unproductive enzyme–substrate complex after the simultaneous binding of two or more substrate molecules to the active site. Here, we show that a single point mutation (L177W) in the haloalkane dehalogenase LinB causes strong substrate inhibition. Surprisingly, a global kinetic analysis suggested that this inhibition is caused by binding of the substrate to the enzyme–product complex. Molecular dynamics simulations clarified the details of this unusual mechanism of substrate inhibition: Markov state models indicated that the substrate prevents the exit of the halide product by direct blockage and/or restricting conformational flexibility. The contributions of three residues forming the possible substrate inhibition site (W140A, F143L and I211L) to the observed inhibition were studied by mutagenesis. An unusual synergy giving rise to high catalytic efficiency and reduced substrate inhibition was observed between residues L177W and I211L, which are located in different access tunnels of the protein. These results show that substrate inhibition can be caused by substrate binding to the enzyme–product complex and can be controlled rationally by targeted amino acid substitutions in enzyme access tunnels. RSC 2021-01-11 /pmc/articles/PMC8341658/ /pubmed/34458806 http://dx.doi.org/10.1039/d0cb00171f Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Chemistry
Kokkonen, Piia
Beier, Andy
Mazurenko, Stanislav
Damborsky, Jiri
Bednar, David
Prokop, Zbynek
Substrate inhibition by the blockage of product release and its control by tunnel engineering
title Substrate inhibition by the blockage of product release and its control by tunnel engineering
title_full Substrate inhibition by the blockage of product release and its control by tunnel engineering
title_fullStr Substrate inhibition by the blockage of product release and its control by tunnel engineering
title_full_unstemmed Substrate inhibition by the blockage of product release and its control by tunnel engineering
title_short Substrate inhibition by the blockage of product release and its control by tunnel engineering
title_sort substrate inhibition by the blockage of product release and its control by tunnel engineering
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8341658/
https://www.ncbi.nlm.nih.gov/pubmed/34458806
http://dx.doi.org/10.1039/d0cb00171f
work_keys_str_mv AT kokkonenpiia substrateinhibitionbytheblockageofproductreleaseanditscontrolbytunnelengineering
AT beierandy substrateinhibitionbytheblockageofproductreleaseanditscontrolbytunnelengineering
AT mazurenkostanislav substrateinhibitionbytheblockageofproductreleaseanditscontrolbytunnelengineering
AT damborskyjiri substrateinhibitionbytheblockageofproductreleaseanditscontrolbytunnelengineering
AT bednardavid substrateinhibitionbytheblockageofproductreleaseanditscontrolbytunnelengineering
AT prokopzbynek substrateinhibitionbytheblockageofproductreleaseanditscontrolbytunnelengineering